# PIVKA-II Combined With Alpha-Fetoprotein for Diagnostic and Prognostic Value of Hepatic Tumors in Infants

> **NCT03645655** · — · COMPLETED · sponsor: **Shanghai Children's Medical Center** · enrollment: 257 (actual)

## Conditions studied

- Hepatoblastoma
- Hepatic Hemangioendothelioma

## Interventions

- **DIAGNOSTIC_TEST:** PIVKA-II

## Key facts

- **NCT ID:** NCT03645655
- **Lead sponsor:** Shanghai Children's Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-01
- **Primary completion:** 2020-09-30
- **Final completion:** 2021-06-30
- **Target enrollment:** 257 (ACTUAL)
- **Last updated:** 2021-07-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03645655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03645655, "PIVKA-II Combined With Alpha-Fetoprotein for Diagnostic and Prognostic Value of Hepatic Tumors in Infants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03645655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*